Selective Inhibition of Nuclear Export (SINE) and Canine Osteosarcoma
Osteosarcoma is a common cancer diagnosed in dogs, particularly in large breed dogs. While several chemotherapy protocols have been shown to provide modest management of the onset of metastasis (spread of cancer), we are continuously looking for additional treatments that may extend survival time. Carboplatin is a widely accepted chemotherapy agent used in treatment of osteosarcoma. The results of this study will allow us to determine if dogs can successfully tolerate carboplatin and a new drug called Laverdia-CA1 (verdinexor) in a combination protocol.
About Osteosarcoma
Background
Osteosarcoma (OS) accounts for 80% to 90% of canine primary bone tumors. Although rare in the canine population, the rate outnumbers that of the human population, with a lifetime incidence risk about 30 to 50 times higher within the overall canine population. Breed-specific incidence rates of OS differ largely, and estimates within certain breeds even show a lifetime risk exceeding 10%, thereby affecting a substantial number of these dogs. Most commonly, OS is diagnosed in middle-aged to older dogs, with a median age of 7 yr. It is well-recognized that giant and large breed dogs are at increased risk of developing OS; however, body size alone cannot explain the variation in incidence between different breeds of dogs, as the risk appears to differ extensively among certain breeds of similar body size.
Causes
Several studies have demonstrated similarities between canine and human OS at the molecular level by showing comparable expression of different proteins.
Diagnosis
Diagnosis is based on biopsy results obtained from affected tissues.
Treatment
No preventative measures are currently available. Median survival time for dogs with primary bone cancer of the appendicular skeleton, treated with surgery and chemotherapy, ranges from 5 to 13 months provided there are no visible metastasis at the time of diagnosis, in which case median survival time drops to about 2 months.
Eligibility
Patients must have been previously treated at Cornell University Hospital for Animals
Your dog has had limb amputation due to osteosarcoma
Patients must had been diagnosed with osteosarcoma and had limb amputation at Cornell University Hospital for Animals previously.
You dog has NOT received any chemotherapy
Patients must not have received chemotherapy treatment previously
Compensation
Laverdia-CA1 Free of Charge
Sponsor will cover some of the costs:
$150 per carboplatin visit (up to $600 total)
$25 Per bloodwork visit (up to $100 total)
10% discount on vet visit cost
This study is sponsored by the Cornell Margaret and Richard Riney Canine Health Center. Laverdia-CA1 (verdinexor) will be provided free of charge. The sponsor will cover some of the costs you incur during carboplatin treatment. This will include $150 at each carboplatin visit (up to $600 total) and $25 at each bloodwork visit (up to $100 total). You will receive a 10% discount on your bill. You are responsible for all additional costs. Any tests or procedures unrelated to the study are your responsibility.
Owner Responsibilities
Administer medication as directed
Return to CUHA for follow-up appointments
This is a 12 week study. You are responsible for administering study medications as directed and must return your dog to CUHA for follow-up appointments according to a specific timeline. All study procedures, time requirements, and responsibilities will be provided to you in a project outline.
Location
1. Cornell University Hospital for Animals (CUHA)
930 N Campus, Ithaca, NY 14853
(607) 253-3060
Study Team
Carol Frederick
Clinical Trials Coordinator
Carol graduated from SUNY Delhi in 1994 and became an LVT. She spent 2 years in private practice, then moved to the emergency and critical care department at Cornell University Hospital for Animals. She obtained her technician specialty in ECC in 2007. After 21 years in ECC she moved to clinical trials, and now is the lead trials coordinator at Cornell.
